Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CeriBell (NASDAQ: CBLL) had its price target raised by analysts at TD Cowen from $31.00 to $36.00. They now have a "buy" rating on the stock.
CeriBell (NASDAQ: CBLL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $31.00 to $33.00. They now have a "buy" rating on the stock.
CeriBell (NASDAQ: CBLL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $30.00 to $31.00. They now have a "buy" rating on the stock.
Ceribell Reports Third Quarter 2024 Financial Results